

Pharmacotherapy of Type 2 Diabetes Mellitus (T2DM) in Clinical Practice: a comprehensive review of the treatment options

Agede O.A..^{1,2}, Olorundare O.E..¹, Oyedepo D.S..², Sanni N..², Bojuwoye M.O..², Engmann S.T..^{3,4}, Alaofin W.A..², Wasagu, I.M..⁵

¹Department of Pharmacology and Therapeutics, University of Ilorin, Nigeria.

²Department of Medicine, University of Ilorin and University of Ilorin Teaching Hospital, Nigeria.

³Manna Mission Hospital, Accra, Ghana

⁴Department of Dietetics, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana

⁵Department of Medicine, Usmanu Danfodiyo University Teaching Hospital, Nigeria

Corresponding Author's Email: niffynimmy@gmail.com; agede.oa@unilorin.edu.ng

Received: September 1, 2024

Accepted for publication: November 10, 2024

Published online: December 23, 2024

Abstract

Introduction: Type 2 Diabetes Mellitus (T2DM) poses a significant global health challenge, necessitating effective treatment strategies to manage its complex pathophysiology. This review critically examined the current treatment regimens employed in clinical practice in managing T2DM.

Methods: This was a narrative review. A detailed electronic search of published articles, from 2004 to 2024, on diabetes mellitus care and treatment using pharmacological and non-pharmacological approaches was conducted. Searches were performed on PubMed, Cochrane libraries, Google and Semantic Scholar. Advanced Boolean searches were utilized for focused results, limited to English language articles.

Conclusion: The review aims to contribute valuable insights to clinicians, researchers, and healthcare professionals involved in the care and treatment of individuals with T2DM, fostering an evidence-based and patient-centered approaches to diabetes management will reduce the burden of the disease in terms of morbidity and mortality.

Keywords: Type 2 DM, Pharmacotherapy, Treatment, Clinical, Drug.

1. Introduction

Type 2 Diabetes Mellitus (T2DM) has emerged as a global health epidemic, presenting a substantial and escalating challenge to public health systems worldwide. The prevalence of T2DM has reached alarming proportions, with an estimated 463 million adults affected globally in 2019, and projections indicating a rise to 700 million by 2045¹. This upsurge is closely linked to urbanization, sedentary lifestyles, and an aging population. T2DM significantly contributes to the global burden of diseases, being a major cause of morbidity and mortality. It is a pivotal risk factor for cardiovascular diseases, renal complications, and a range of other debilitating conditions². The economic impact is profound, with soaring

healthcare costs and productivity losses attributable to T2DM and its associated complications³.

Despite its pervasive impact, T2DM is a preventable and manageable condition⁴. Advances in medical science and healthcare delivery have led to the development of various therapeutic modalities aimed at glycemic control and prevention of complications⁵. However, the rapidly evolving landscape of T2DM management necessitates a comprehensive review to consolidate current knowledge and guide future interventions⁶. A thorough understanding of the treatment regimens employed in clinical practice is essential for healthcare professionals, policymakers, and researchers

striving to enhance patient outcomes and mitigate the socio-economic burden associated with T2DM.

The rationale for this review stems from the critical need to synthesize existing evidence on T2DM treatment regimens. The dynamic nature of diabetes management, characterized by constant updates in guidelines and the introduction of novel therapies, underscores the importance of an up-to-date review. By critically evaluating current approaches, identifying gaps in knowledge, and highlighting emerging trends, this review aims to contribute to the ongoing discourse on optimizing T2DM care. Additionally, the diverse demographic and lifestyle factors influencing T2DM prevalence warrant an exploration of tailored therapeutic strategies. Understanding the nuances of treatment regimens and their effectiveness in different populations is crucial for advancing precision medicine approaches in T2DM management.

Methods: This was a narrative review. A detailed electronic search of published articles, from 2004 to 2024, on diabetes mellitus care and treatment using pharmacological and non-pharmacological approaches was conducted. Searches were performed on PubMed, Cochrane libraries, Google and Semantic Scholar. Advanced Boolean searches were utilized for focused results, limited to English language articles.

Significance of T2DM as a Global Health Concern:

T2DM stands out as a critical global health concern due to its escalating prevalence, imposing substantial morbidity and mortality burdens, and inflicting significant economic consequences on healthcare systems. With an estimated 463 million adults affected in 2019 and a projected surge to 700 million by 2045, the pandemic proportions of T2DM demand urgent attention⁷. Beyond its prevalence, T2DM substantially elevates the risk of cardiovascular diseases, chronic kidney disease, neuropathy, and retinopathy, contributing to increased morbidity and mortality globally⁸. The economic ramifications are profound, as T2DM accounts for a considerable portion of global healthcare expenditure, emphasizing the need for effective preventive strategies and

sustainable management approaches⁹. Moreover, T2DM exacerbates health disparities, disproportionately affecting vulnerable populations, highlighting the imperative to address these inequalities in diabetes prevention and management efforts.

Epidemiology of T2DM: A Global Perspective

T2DM has evolved into a staggering global health concern, with its prevalence and incidence undergoing an alarming surge. According to the International Diabetes Federation (IDF), an estimated 463 million adults were living with diabetes in 2019, a number anticipated to escalate to 700 million by 2045 if current trends persist¹⁰. This upswing is not confined to high-income nations; it permeates low- to middle-income countries as well, with regions such as the Middle East, North Africa, and Southeast Asia witnessing disproportionate increases¹¹. The burden of T2DM is also undergoing a demographic shift, with a rising prevalence among younger populations¹². This complex epidemiological landscape necessitates a comprehensive understanding of the factors influencing T2DM's global prevalence.

The impact of T2DM on public health is multifaceted, extending far beyond the sheer numbers. Diabetes stands as a major risk factor for a spectrum of health complications, including cardiovascular diseases, chronic kidney disease, retinopathy, and neuropathy¹³. These complications not only diminish the quality of life for affected individuals but also impose a substantial burden on healthcare systems. The economic ramifications are substantial, encompassing direct medical costs, indirect costs related to productivity losses, and expenses associated with diabetes-related complications¹⁴.

Pathophysiology of T2DM: Unraveling the Molecular Puzzle

Insulin Resistance: A cornerstone in the pathophysiology of T2DM is insulin resistance, where target tissues, primarily muscle, adipose, and liver cells, exhibit reduced responsiveness to insulin. This impedes glucose uptake and

utilization, leading to elevated blood glucose levels. Molecular mechanisms underlying insulin resistance involve disruptions in insulin signaling pathways, including phosphorylation cascades and altered expression of key proteins like glucose transporters¹⁵. Lifestyle factors, such as sedentary behavior and obesity, significantly contribute to the development of insulin resistance¹⁶.

Beta-Cell Dysfunction: Progressive deterioration in beta-cell function, responsible for insulin secretion, is another pivotal aspect of T2DM pathophysiology. Chronic exposure to elevated glucose levels and increased demand for insulin secretion contribute to beta-cell stress and dysfunction. Genetic predispositions, coupled with environmental factors, amplify this dysfunction, compromising the delicate balance of insulin release and glucose control¹⁷. Understanding the intricate molecular mechanisms underlying beta-cell failure is crucial for devising interventions that target not only insulin resistance but also beta-cell dysfunction in T2DM¹⁸.

Glucose Homeostasis: The orchestration of glucose homeostasis is disrupted in T2DM, marked by an imbalance between glucose production and utilization. Hepatic gluconeogenesis, the process of glucose synthesis in the liver, becomes dysregulated, contributing to sustained hyperglycemia. Additionally, impaired insulin action in peripheral tissues and altered incretin hormone signaling further exacerbate glucose dysregulation in T2DM¹⁹. Deciphering the molecular intricacies of glucose homeostasis provides a foundation for developing targeted therapeutic strategies aimed at restoring glycemic control.

First Line Treatment Approaches: Nurturing Health through Lifestyle and Metformin

Life-Changing Lifestyle Modifications: The cornerstone of T2DM management lies in lifestyle modifications, encompassing dietary adjustments and increased physical activity. Dietary interventions, emphasizing a balanced, low-glycemic index diet rich in fiber, have demonstrated efficacy in glycemic control and weight management²⁰. Concurrently,

engaging in regular physical activity enhances insulin sensitivity, facilitating glucose uptake and utilization by tissues²¹. These lifestyle changes not only address the root causes of T2DM but also contribute to overall cardiovascular health and weight management.

Dietary Interventions for Glycemic Control: Dietary strategies in T2DM management extend beyond general healthy eating principles. Specific dietary interventions, such as adopting a Mediterranean diet characterized by high monounsaturated fats and low glycemic load, showcase benefits in glycemic control and cardiovascular risk reduction²². Additionally, approaches like intermittent fasting exhibit promising outcomes in improving insulin sensitivity and metabolic health²³. Tailoring dietary recommendations to individual preferences and cultural contexts ensures sustainable adherence, contributing to long-term glycemic control.

Empowering with Physical Activity: Physical activity emerges as a potent ally in T2DM management, offering benefits beyond glycemic control. Exercise interventions, including aerobic and resistance training, contribute to improved insulin sensitivity, reduced adiposity, and enhanced cardiovascular health²⁴. Moreover, the psychological well-being associated with regular physical activity positively influences overall diabetes management. Personalized exercise prescriptions, considering individual fitness levels and preferences, form an integral component of comprehensive T2DM care.

Metformin as the Pharmacological Foundation: Metformin stands as the first-line pharmacological agent in T2DM management. Its role extends beyond glycemic control, encompassing weight management, cardiovascular protection, and improved insulin sensitivity²⁵. Metformin's safety profile, cost-effectiveness, and evidence of long-term benefits position it as a cornerstone in treatment initiation. However, individualization of treatment plans, considering patient characteristics and preferences, ensures optimized therapeutic outcomes.

Second Line Pharmacological Agents: Expanding Horizons in T2DM Management

When lifestyle modifications and first-line treatments, primarily metformin, fail to achieve glycemic targets in T2DM, second-line pharmacological agents become pivotal. This phase involves selecting therapies tailored to individual needs and characteristics. Various classes of medications offer distinct mechanisms of action, addressing specific aspects of glucose metabolism and associated complications.

Sulfonylureas and Insulin Secretion: Sulfonylureas, such as glipizide and glyburide, have long been considered traditional second-line options. They enhance insulin secretion from pancreatic beta cells, aiding glucose control²⁶. However, concerns about hypoglycemia and declining efficacy over time have prompted exploration of newer alternatives. Their use often necessitates vigilant monitoring to mitigate potential adverse effects.

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): GLP-1 RAs, exemplified by exenatide, liraglutide, and semaglutide, offer an innovative approach by mimicking the action of endogenous GLP-1. These agents enhance glucose-dependent insulin secretion, suppress glucagon release, and promote satiety, leading to weight loss²⁷. Beyond glycemic control, GLP-1 RAs exhibit cardiovascular benefits, making them valuable additions, particularly in patients with atherosclerotic cardiovascular disease.

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: SGLT-2 inhibitors, including canagliflozin and dapagliflozin, target renal glucose reabsorption, promoting glycosuria. This unique mechanism reduces hyperglycemia, induces weight loss, and predisposes the patient to recurrent urinary tract infection. This class also demonstrates cardiovascular and renal protective effects²⁸. Their role in heart failure management further extends their utility in T2DM patients with concurrent cardiovascular conditions.

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: DPP-4 inhibitors, like sitagliptin and saxagliptin, modulate incretin hormones, prolonging their action. This leads to improved glycemic control by enhancing insulin secretion and suppressing glucagon release, all while preserving body weight²⁹. DPP-4 inhibitors are well-tolerated and offer a valuable option, particularly when weight neutrality is a priority.

Insulin Therapy in T2DM: Navigating Treatment Challenges

In the management of T2DM, insulin therapy plays a crucial role, particularly when other interventions fail to maintain glycemic control. The decision to initiate insulin often stems from the progressive nature of T2DM, marked by declining beta-cell function and increased insulin resistance. Insulin therapy becomes indispensable when oral medications and injectable non-insulin agents no longer suffice to achieve target HbA1c levels³⁰. Despite its efficacy, insulin initiation can pose challenges related to patient acceptance, regimen complexity, and concerns about hypoglycemia and weight gain.

Types of Insulin and Treatment Approaches: Various insulin formulations cater for the diverse needs of individuals with T2DM. Basal insulin provides a steady release mimicking endogenous insulin secretion, while bolus or prandial insulin addresses postprandial glucose excursions. A common approach is the initiation of basal insulin, often followed by the addition of prandial insulin if glycemic targets remain unmet³¹. Long-acting insulin analogs, such as insulin glargine and insulin detemir, offer advantages in terms of reduced hypoglycemic risk and once-daily dosing.

Challenges and Strategies in Insulin Therapy: Adherence to insulin regimens can be challenging due to factors like injection-related anxiety, lifestyle disruptions, and misconceptions about insulin use. Addressing these challenges requires a collaborative effort involving healthcare providers, patients, and support networks. Patient education plays a pivotal role in fostering self-efficacy and dispelling

fears associated with insulin therapy³². Additionally, advancements in insulin delivery systems, such as insulin pens and continuous subcutaneous insulin infusion (CSII) devices, enhance convenience and may contribute to improved adherence.

Combinatorial Approaches in T2DM Management: Maximizing Therapeutic Synergy

The multifaceted nature of T2DM often necessitates a combination of therapeutic strategies to achieve optimal glycemic control. Combinatorial approaches involve the simultaneous or sequential use of multiple agents with distinct mechanisms of action to address the underlying pathophysiological factors contributing to T2DM progression³³. These approaches aim to capitalize on the complementary effects of different drug classes, offering enhanced glycemic control while minimizing adverse effects. Combinatorial therapy becomes particularly relevant when monotherapy or dual therapy fails to achieve and maintain target glycemic levels.

Optimizing Treatment through Combinations: Combinatorial approaches typically involve the integration of oral antidiabetic agents, injectable medications, and lifestyle modifications. Common combinations include the use of metformin with sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, or glucagon-like peptide-1 receptor agonists (GLP-1 RAs)³⁴. These combinations offer synergistic effects, such as improved insulin sensitivity, reduced hepatic glucose production, and enhanced incretin-mediated glucose-dependent insulin secretion. Understanding the patient's individual profile, preferences, and tolerability is crucial in tailoring combinatorial approaches for personalized T2DM management.

Emerging Therapeutic Modalities in T2DM Management: Paving the Way for Novel Interventions

Novel Drug Targets: The evolving landscape of T2DM management is marked by a continuous quest for innovative therapeutic modalities, driven by an increased understanding of the intricate molecular pathways involved in glucose homeostasis. Identification of novel drug targets remains a crucial aspect, aiming to develop interventions that not only enhance glycemic control but also address the underlying pathophysiological mechanisms³⁵. Recent research has delved into targets such as the fibroblast growth factor (FGF) system, dual-acting peptide receptor agonists, and novel mechanisms involving gut hormones and bile acids³⁶. These investigational targets hold promise for developing drugs that offer improved efficacy, safety profiles, and patient adherence.

Investigational Therapies: The pharmaceutical industry's commitment to advancing T2DM therapeutics is evident in the exploration of investigational therapies that extend beyond conventional drug classes³⁷. Ongoing clinical trials assess the safety and efficacy of various compounds, including innovative oral antidiabetic agents, injectables, and gene-based therapies³⁸. Some investigational therapies target specific pathways implicated in insulin resistance, beta-cell dysfunction, or glucagon dysregulation. As these promising modalities progress through the stages of clinical development, they bring hope for expanding the armamentarium of T2DM treatments, ultimately providing clinicians with additional options for personalized patient care³⁹.

Patient-Centered Approach and Personalized Medicine in T2DM Management: A Paradigm Shift for Tailoring Treatment Plans

Tailoring Treatment Plans: The shift towards a patient-centered approach in T2DM management underscores the importance of individualized care strategies⁴⁰. Recognizing the heterogeneity of T2DM manifestations, tailoring treatment plans becomes imperative for optimizing therapeutic outcomes⁴¹. Personalization involves considering factors such as patient preferences, comorbidities, lifestyle, and genetic

predispositions⁴². This approach extends beyond glycemic control to address the holistic well-being of individuals with T2DM, fostering a more comprehensive and effective management paradigm⁴³. Tailored interventions may include personalized dietary plans, exercise regimens, and pharmacotherapy to meet the unique needs of each patient⁴⁴.

Patient Education and Empowerment: Empowering patients through education is a cornerstone of patient-centered care in T2DM⁴⁵. Informed and engaged patients are better equipped to actively participate in their treatment plans, make lifestyle modifications, and adhere to prescribed therapies⁴⁶. Patient education initiatives focus on enhancing health literacy, providing practical guidance on self-monitoring of blood glucose, and fostering a deeper understanding of the importance of medication adherence⁴⁷. Empowered patients are more likely to embrace lifestyle modifications, leading to improved glycemic control and long-term health outcomes⁴⁸.

Interventions to Improve access to Medicines for People living with Diabetes in Africa and Nigeria

National Policy Framework: Countries like Nigeria and Ethiopia have developed national guidelines and policies to integrate diabetes care into primary healthcare and thereby making essential medicines (glucose lowering agents) available to people living with diabetes at primary healthcare level^{49,50}.

Community Based Programs: Initiatives like diabetes self-management education (DSME) focus on community engagement to enhance patient education, access to medication and adherence to treatment, which can reduce overall healthcare cost⁵¹.

Public awareness: Efforts are underway to increasing awareness about diabetes care, and importance of medication adherence with the aim of mobilizing political will and resources to improve antidiabetic drugs availability especially in rural communities where access to medication is limited^{52,53}.

Challenges and Limitations in the Management of T2DM: Navigating Adverse Effects, Treatment Adherence, and Economic Considerations

Adverse Effects of Medications: The pharmacological management of T2DM is associated with potential adverse effects, posing challenges for both patients and healthcare providers⁵⁴. Commonly prescribed medications, such as oral anti-diabetic agents and insulin, may elicit side effects ranging from gastrointestinal disturbances to hypoglycemia⁵⁵. Balancing the benefits of glycemic control with the risk of adverse effects requires a nuanced approach⁵⁶. Tailoring treatment regimens, considering individual patient profiles, and vigilant monitoring can help mitigate these challenges, ensuring the overall safety and tolerability of the prescribed medications⁵⁷.

Treatment Adherence: A critical hurdle in T2DM management is ensuring sustained treatment adherence among patients⁵⁸. Complex dosing regimens, medication costs, and lifestyle modifications contribute to adherence challenges. Non-adherence can lead to suboptimal glycemic control, increased risk of complications, and higher healthcare costs⁵⁹. Implementing patient-centered strategies, such as simplified medication regimens, patient education programs, and leveraging technology for medication reminders, is vital to enhance treatment adherence⁶⁰. Addressing psychosocial factors and fostering a collaborative patient-healthcare provider relationship are essential components in overcoming this challenge⁶¹.

Economic Considerations: The economic burden of T2DM management encompasses direct medical costs, indirect costs related to productivity loss, and the economic impact of diabetes-related complications. Affordability and accessibility of medications, diagnostic tests, and regular follow-up care contribute to the economic considerations associated with T2DM⁶². Disparities in healthcare access and socioeconomic factors further exacerbate the economic challenges⁶³. Policymakers and healthcare stakeholders need to address

these economic considerations through interventions that enhance healthcare affordability, improve access to essential medications, and implement strategies to prevent and manage T2DM and complications in a cost effective way⁶⁴.

Conclusion

Comprehensive review of the treatment of T2DM underscores the multifaceted nature of its management. Lifestyle modifications, personalized medicine, and emerging therapies offer diverse strategies. Clinicians should prioritize patient education, tailoring interventions to specific challenges like medication side effects, economic considerations, and fostering a patient-centered approach for optimal treatment outcomes.

References

1. Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., *et al.* IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes research and clinical practice* 138, 271-81 (2018).
2. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *The lancet* 375(9733), 2215-22 (2010).
3. Bommer, C., Heesemann, E., Sagalova, V., Manne-Goehler, J., Atun, R., Bärnighausen, T., *et al.* The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. *The lancet Diabetes & endocrinology* 5(6), 423-30 (2017).
4. Rocha, V.Z., Santos, R.D. Subclinical carotid vascular disease and risk factors for atherosclerosis in type 1 and type 2 diabetes. *Archives of Endocrinology and Metabolism* 61, 105-7 (2017).
5. Kim, N.H. Diabetes mellitus, still major threat to mortality from various causes. *Diabetes & Metabolism Journal* 43(3), 273-75 (2019).
6. Zhang, L., Li, X., Wolfe, C. D., O'Connell, M. D., Wang, Y. Diabetes as an independent risk factor for stroke recurrence in ischemic stroke patients: an updated meta-analysis. *Neuroepidemiology* 55(6), 427-35 (2021).
7. Boyle, J. P., Honeycutt, A. A., Narayan, K. V., Hoerger, T. J., Geiss, L. S., Chen, H., *et al.* & Thompson, T. J. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. *Diabetes care* 24(11), 1936-40 (2001).
8. Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. *Diabetes care* 27(12), 2836-42 (2004).
9. Danaei, G., Lawes, C.M., Vander Hoorn, S., Murray, C.J., Ezzati, M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. *The Lancet* 368(9548), 1651-59 (2006).
10. Wang, H., Li, N., Chivese, T., Werfalli, M., Sun, H., Yuen, L., *et al.* IDF diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group's Criteria. *Diabetes research and clinical practice* 183, 109-50 (2022).
11. da Rocha Fernandes, J., Ogurtsova, K., Linnenkamp, U., Guariguata, L., Seuring, T., Zhang, P., *et al.* IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. *Diabetes research and clinical practice* 117, 48-54 (2016).
12. American Diabetes Association, Diabetes care in the hospital: Standards of Medical Care in Diabetes. *Diabetes Care* 41(1), S144-S151 (2018).
13. Seuring, T., Archangelidi, O., Suhrcke, M. The economic costs of type 2 diabetes: a global

- systematic review. *Pharmacoeconomics* 33, 811-31 (2015).
14. Afroz, A., Alramadan, M. J., Hossain, M. N., Romero, L., Alam, K., Magliano, D. J. *et al.* Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review. *BMC health services research* 18(1), 1-10 (2018).
15. Samuel, V.T., Shulman, G.I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. *The Journal of clinical investigation* 126(1), 12-22 (2016).
16. DeFronzo, R.A., Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes care* 32(2), S157 (2009).
17. Prentki, M., Nolan, C.J. Islet β cell failure in type 2 diabetes. *The Journal of clinical investigation* 116(7), 1802-12 (2006).
18. Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., Butler, P.C. β -cell deficit and increased β -cell apoptosis in humans with type 2 diabetes. *Diabetes* 52(1), 102-10 (2003).
19. Kahn, S. E., Cooper, M. E., Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *The Lancet* 383(9922), 1068-83 (2014).
20. Thomas, D., Elliott, E. J., Naughton, G.A. Exercise for type 2 diabetes mellitus. *Cochrane database of systematic reviews* (3), (2006)
21. Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., *et al.* Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. *Diabetes care* 33(12), e147-e167 (2010).
22. Salas-Salvadó, J., Bulló, M., Babio, N., Martínez-Gonzalez, M. A., Ibarrola-Jurado, N., Basora, J., *et al.* Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial *Diabetes care*, 34(1), 14-19 (2011).
23. Antoni, R., Johnston, K. L., Collins, A. L., Robertson, M. D. Effects of intermittent fasting on glucose and lipid metabolism. *Proceedings of the Nutrition Society* 76(3), 361-68 (2017).
24. Umpierre, D., Ribeiro, P. A., Kramer, C. K., Leitao, C. B., Zucatti, A. T., Azevedo, M. J., *et al.* Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA* 305(17), 1790-99 (2011).
25. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes. *Diabetes care* 44(1), S111-S124 (2021).
26. Feldman, J. M. Glyburide: a second-generation sulfonylurea hypoglycemic agent: history, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* 5(2), 43-62 (1985).
27. Drucker, D. J. Enhancing incretin action for the treatment of type 2 diabetes. *Diabetes care* 26(10), 2929-40 (2003).
28. Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., Davies, M. J. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. *Diabetes, Obesity and Metabolism* 18(8), 783-94 (2016).
29. Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow, T., *et al.* Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. *Clinical therapeutics* 34(6), 1247-58 (2012).
30. Khunti, K., Damci, T., Meneghini, L., Pan, C. Y., Yale, J. F. Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin

- initiation in people with poorly controlled type 2 diabetes in routine clinical practice. *Diabetes, Obesity and Metabolism* 14(7), 654-61 (2012).
31. Riddle, M. C., Rosenstock, J., Gerich, J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes care* 26(11), 3080-86 (2003).
 32. Peyrot, M., Barnett, A. H., Meneghini, L. F., Schumm-Draeger, P. M. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. *Diabetic Medicine* 29(5), 682-689 (2012).
 33. Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., *et al.* 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes care* 43(2), 487-93 (2020).
 34. Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., *et al.* Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes care*, 38(1), 140-49 (2015).
 35. Yang, X.D., Yang, Y.Y. Ferroptosis as a novel therapeutic target for diabetes and its complications. *Frontiers in Endocrinology* 13, 853822 (2022).
 36. Xu, Y. X., Pu, S. D., Li, X., Yu, Z. W., Zhang, Y. T., Tong, X. W., *et al.* Exosomal ncRNAs: Novel therapeutic target and biomarker for diabetic complications. *Pharmacological research* 178, 106135 (2022).
 37. Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., *et al.* Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. *The Lancet* 392(10160), 2180-93 (2018).
 38. Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., *et al.* LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. *Molecular metabolism* 18, 3-14 (2018).
 39. Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., *et al.* Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *The Lancet*, 375(9724), 1447-56 (2010).
 40. American Diabetes Association. Glycemic targets: standards of medical care in diabetes. *Diabetes Care* 44(1), S73-S84 (2021).
 41. Assessment, G. Glycemic targets: standards of medical care in diabetes. *Diabetes Care* 45, S83-87 (2022).
 42. Bergenstal, R. M., Mullen, D. M., Strock, E., Johnson, M. L., Xi, M. X. Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes. *Journal of Diabetes and its Complications* 36(3), 108106 (2022).
 43. Messer, L. H., Berget, C., Pyle, L., Vigers, T., Cobry, E., Driscoll, K. A., Forlenza, G. P. Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes. *Diabetes Technology & Therapeutics* 23(12), 837-43 (2021).
 44. De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., Peleshok, J. Tirzepatide for the treatment of adults with type 2

- diabetes: An endocrine perspective. *Diabetes, Obesity and Metabolism* 25(1), 3-17 (2023).
45. Coulter, A., Ellins, J. Effectiveness of strategies for informing, educating, and involving patients. *BMJ* 335(7609), 24-27 (2007).
 46. Richards, T. Partnership with patients: Patients want more than simply information; they need involvement too. *BMJ* 316(7125), 85-86 (1998).
 47. Glanville, J., Haines, M., Auston, I. Finding information on clinical effectiveness. *BMJ* 317(7152), 200-3 (1998).
 48. Garlick, P. B., Brown, G. Widening participation in medicine. *BMJ* 336(7653), 1111-13 (2008).
 49. Chinenye, S., Ogu, R., Korubo, I. Diabetes Advocacy and Care in Nigeria: A Review. *The Nigerian Health Journal*. 15 (4), 145-50 (2015)
 50. Deressa, H.D., Abuye, H., Adinew, A. Access to essential medicines for diabetes care: availability, price, and affordability in central Ethiopia. *glob health res policy*. 9(12), 412-24 (2024).
 51. Kiconco, R., Lumumba, SA., Bagenda, CN., Atwine, R., Ndarubweine, J., Rugera, SP. Insulin therapy among diabetic patients in rural communities of Sub-Saharan Africa: a perspective review. *Ther Adv Endocrinol Metab*. 15, 1-14 (2024).
 52. Tella, EE., Yunusa, I., Hassan, JH., Chindo, IA., Oti, VB. Prevalence, Contributing Factors and Management Strategies (Self-Management Education) of Type 2 Diabetes Patients in Nigeria: A Review. *Int J Diabetes Clin Res*. 8:148-54 (2021).
 53. Ekpör, E., Osei, E., Akyirem, S. Prevalence and predictors of traditional medicine use among persons with diabetes in Africa: a systematic review. *International Health*. 16(3), 252-60 (2024).
 54. American Diabetes Association. Glycemic targets: standards of medical care in diabetes. *Diabetes care* 41(1), S55-S64 (2018).
 55. American Diabetes Association. Glycemic targets: standards of medical care in diabetes. *Diabetes care* 43(1), S66-S76 (2020).
 56. Doyle-Delgado, K., Chamberlain, J. J., Shubrook, J. H., Skolnik, N., Trujillo, J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American diabetes association's standards of medical care in diabetes clinical guideline. *Annals of Internal medicine* 173(10), 813-21 (2020).
 57. American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee: (2022). 6. Glycemic targets: standards of medical care in diabetes. *Diabetes Care* 45(1), S83-S96 (2022).
 58. American Diabetes Association. Glycemic targets: standards of medical care in diabetes. *Diabetes care* 42(1), S61-S70 (2019).
 59. American Diabetes Association. Diabetes technology: standards of medical care in diabetes. *Diabetes Care* 44(1), S85-S99 (2021).
 60. American Diabetes Association. Diabetes technology: standards of medical care in diabetes. *Diabetes Care* 43(1), S77-S88 (2020).
 61. American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee. Diabetes technology: standards of medical care in diabetes. *Diabetes Care* 45(1), S97-S112 (2022).
 62. Ismail-Beigi, F. Glycemic management of type 2 diabetes mellitus. *New England Journal of Medicine* 366(14), 1319-27 (2012).
 63. Davis, S., Alonso, M. D. Hypoglycemia as a barrier to glycemic control. *Journal of Diabetes and its Complications* 18(1), 60-68 (2004).

64. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *New England journal of medicine* 358(24), 2560-72 (2008).